MX373177B - Métodos de tratamiento de disquinesia y trastornos relacionados. - Google Patents

Métodos de tratamiento de disquinesia y trastornos relacionados.

Info

Publication number
MX373177B
MX373177B MX2015013151A MX2015013151A MX373177B MX 373177 B MX373177 B MX 373177B MX 2015013151 A MX2015013151 A MX 2015013151A MX 2015013151 A MX2015013151 A MX 2015013151A MX 373177 B MX373177 B MX 373177B
Authority
MX
Mexico
Prior art keywords
dyskinesia
related disorders
methods
treatment methods
disorders
Prior art date
Application number
MX2015013151A
Other languages
English (en)
Other versions
MX2015013151A (es
Inventor
Andrew G Reaume
John Ciallella
John Gruner
Michael S Saporito
Original Assignee
Melior Pharmaceuticals Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melior Pharmaceuticals Ii Llc filed Critical Melior Pharmaceuticals Ii Llc
Publication of MX2015013151A publication Critical patent/MX2015013151A/es
Publication of MX373177B publication Critical patent/MX373177B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción describe compuestos y sales de los mismos farmacéuticamente aceptables y composiciones y formulaciones que comprenden los mismos que son útiles en los métodos para tratar la disquinesia y trastornos relacionados, y método para tratar la disquinesia o trastornos relacionados. La presente descripción describe compuestos, composiciones, y formulaciones que comprenden compuestos terapéutica o profilácticamente activos o sales de los mismos farmacéuticamente aceptables para tratar y/o prevenir las disquinesias u otros trastornos, y métodos para tratar la disquinesia u otros trastornos.
MX2015013151A 2013-03-15 2014-03-14 Métodos de tratamiento de disquinesia y trastornos relacionados. MX373177B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361786714P 2013-03-15 2013-03-15
PCT/US2014/029827 WO2014145126A2 (en) 2013-03-15 2014-03-14 Methods of treating dyskinesia and related disorders

Publications (2)

Publication Number Publication Date
MX2015013151A MX2015013151A (es) 2016-04-11
MX373177B true MX373177B (es) 2020-04-24

Family

ID=51538415

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013151A MX373177B (es) 2013-03-15 2014-03-14 Métodos de tratamiento de disquinesia y trastornos relacionados.

Country Status (14)

Country Link
US (6) US9051312B2 (es)
EP (1) EP2970160B1 (es)
JP (1) JP6605447B2 (es)
KR (3) KR20210113429A (es)
CN (1) CN105209445B (es)
AU (1) AU2014233334B2 (es)
BR (1) BR112015023116A2 (es)
CA (1) CA2904539C (es)
EA (1) EA032064B1 (es)
IL (1) IL241114B (es)
MX (1) MX373177B (es)
SG (2) SG10201707560TA (es)
WO (1) WO2014145126A2 (es)
ZA (1) ZA201506705B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3302454T (pt) * 2015-05-26 2021-04-01 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composições para utilização no tratamento da doença de parkinson e distúrbios associados
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
EP4282862A1 (en) * 2022-05-25 2023-11-29 Irbm S.P.A. Flavivirus inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1496056A (fr) * 1964-06-08 1967-09-29 Takeda Chemical Industries Ltd Nouveaux composés chimiques du type sydnonimine
GB1262830A (en) 1970-06-10 1972-02-09 Vni Khim Farmatsevtichesky I I Novel sydnonimine derivative
CA1097659A (en) 1976-11-25 1981-03-17 Roald A. Altshuler Sydnonimine n-acylderivatives and method for preparing same
US4277609A (en) * 1979-08-31 1981-07-07 American Home Products Corporation Sydnone imines
US4446322A (en) * 1980-07-29 1984-05-01 American Home Products Corporation Hydroxyl protected 3-(2-hydroxy-2-phenylethyl)-N-[(phenylamino)carbonyl]sydnone imine intermediates
US4324897A (en) * 1980-10-02 1982-04-13 American Home Products Corporation 1,2,3 Oxadiazolium salts
DE3921796A1 (de) * 1989-07-03 1991-01-17 Cassella Ag Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
WO1993018767A1 (de) * 1992-03-24 1993-09-30 Cassella Aktiengesellschaft Verwendung von sydnoniminen zur behandlung erektiler dysfunktionen
US7064204B2 (en) * 2002-05-30 2006-06-20 King Pharmacueticals Reserch And Development, Inc. Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use
US8691853B2 (en) * 2007-03-14 2014-04-08 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
EP2121785B1 (en) * 2007-03-14 2016-06-01 Caliper Life Sciences, Inc. Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
JP2011529923A (ja) * 2008-08-06 2011-12-15 ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法
WO2011069051A1 (en) * 2009-12-04 2011-06-09 Caliper Life Sciences, Inc. Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20130289019A1 (en) * 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders

Also Published As

Publication number Publication date
WO2014145126A2 (en) 2014-09-18
MX2015013151A (es) 2016-04-11
NZ712291A (en) 2020-10-30
ZA201506705B (en) 2017-09-27
CA2904539A1 (en) 2014-09-18
EA201591480A1 (ru) 2016-03-31
BR112015023116A2 (pt) 2017-07-18
EP2970160A4 (en) 2017-01-25
KR20150132391A (ko) 2015-11-25
IL241114B (en) 2019-07-31
IL241114A0 (en) 2015-11-30
KR102301073B1 (ko) 2021-09-10
US20240408090A1 (en) 2024-12-12
CN105209445B (zh) 2018-01-23
HK1220453A1 (zh) 2017-05-05
US9051312B2 (en) 2015-06-09
AU2014233334B2 (en) 2018-07-19
EP2970160B1 (en) 2020-11-11
SG10201707560TA (en) 2017-11-29
US20170042894A1 (en) 2017-02-16
US12048697B2 (en) 2024-07-30
CA2904539C (en) 2022-05-03
US20190328736A1 (en) 2019-10-31
US10188651B2 (en) 2019-01-29
EA032064B1 (ru) 2019-04-30
KR20210113429A (ko) 2021-09-15
JP6605447B2 (ja) 2019-11-13
US9402830B2 (en) 2016-08-02
US20220331320A1 (en) 2022-10-20
US20140371231A1 (en) 2014-12-18
KR20240004497A (ko) 2024-01-11
WO2014145126A3 (en) 2014-12-18
JP2016514698A (ja) 2016-05-23
EP2970160A2 (en) 2016-01-20
US11351169B2 (en) 2022-06-07
CN105209445A (zh) 2015-12-30
SG11201507257RA (en) 2015-10-29
US20150231116A1 (en) 2015-08-20
AU2014233334A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
MX2015017964A (es) Inhibidores de bromodominio.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
MX386598B (es) Compuestos antibacterianos.
EA202092456A3 (ru) Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
HK1216175A1 (zh) 治療性化合物和組合物
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
MX2015012502A (es) Inhibidores de proteina cinasa dependiente de adn.
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
EA201591509A1 (ru) Ингибиторы cdc7
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CL2015002897A1 (es) Inhibidores de bace1
WO2012158672A3 (en) Compounds for use in treatment of mucositis
MX2015000179A (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
MX373177B (es) Métodos de tratamiento de disquinesia y trastornos relacionados.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
UA91125U (uk) Антибактеріальна композиція

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MELIOR PHARMACEUTICALS II, LLC

FG Grant or registration